ISA Pharmaceuticals to Present Pre-clinical Data on its Protective SLP Therapy Against SARS-CoV-2 at the CIMT Annual Meeting

/in

Oegstgeest, The Netherlands, 27 April 2023 – ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, is pleased to announce that it will be presenting data evaluating the response to its T cell inducing SLP therapy against SARS-CoV-2 in collaboration with the Leiden University Medical Center (LUMC) and […]

Read more

Aldena Therapeutics and Empa Awarded InnoSuisse Funding to Advance STAR Particles as a Novel Drug Delivery Technology for Dermatology

/in

Boston, Massachusetts, April 26, 2023 – Aldena Therapeutics Inc. (Aldena), a private biotech company pioneering siRNA-based therapies for dermatological indications, and Empa, the Swiss Federal research institute for materials science and technology, have been awarded a joint 600’000 CHF grant by InnoSuisse, the Swiss Innovation Agency. This StarCURE grant seeks to co-develop microneedle particles as […]

Read more

Massive investment in fundamental cardiometabolic research addresses a growing global public health crisis

/in

Copenhagen-based research center is awarded up to DKK 1 billion (€134.2 million) from the Novo Nordisk Foundation to support research toward innovative approaches to the diagnosis, prevention, and treatment of cardiometabolic diseases. Read more…

Read more

Alchemab Therapeutics to present data profiling a novel antibody to Huntingtin Exon 1 at the CHDI Annual Huntington’s Disease Therapeutics Conference

/in

Cambridge, UK, April 25, 2023 – Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announced that it will present data on a potential first-in-class disease modifying therapeutic for Huntington’s Disease at the annual CHDI Huntington’s Disease Therapeutics Conference in Dubrovnik, Croatia, 24-27 April 2023. Read more…

Read more

ISA Pharmaceuticals to Attend and Present at Upcoming Scientific and Business Conferences in May and June of 2023

/in

Oegstgeest, The Netherlands, 20 April 2023 – ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, is pleased to announce that it will be participating and presenting in person, at the following scientific and business conferences in May and June of 2023. ISA’s versatile synthetic long peptide (SLP®) […]

Read more